• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酸度响应性纳米平台通过多种途径加重肿瘤缺氧以增强化疗效果。

Acidity-responsive nanoplatforms aggravate tumor hypoxia via multiple pathways for amplified chemotherapy.

作者信息

Yin Jiajia, Wang Chenxi, Zhao Lei, Xu Kang, Guo Yuxin, Song Xuejiao, Shao Jinjun, Xu Huae, Dong Xiaochen

机构信息

Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), School of Physical and Mathematical Sciences, Nanjing Tech University (NanjingTech), Nanjing, 211816, China.

School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou, 221116, China.

出版信息

Biomaterials. 2023 May;296:122094. doi: 10.1016/j.biomaterials.2023.122094. Epub 2023 Mar 15.

DOI:10.1016/j.biomaterials.2023.122094
PMID:36933458
Abstract

Since the hypoxia tumor microenvironment (TME) will not only limit the treatment effect but also cause tumor recurrence and metastasis, intratumoral aggravated hypoxia level induced by vascular embolization is one of the major challenges in tumor therapy. The chemotherapeutic effect of hypoxia-activated prodrugs (HAPs) could be enhanced by the intensified hypoxia, the combination of tumor embolization and HAP-based chemotherapy exhibits a promising strategy for cancer therapy. Herein, an acidity-responsive nanoplatform (TACC NP) with multiple pathways to benefit the hypoxia-activated chemotherapy is constructed by loading the photosensitizer Chlorin e6 (Ce6), thrombin (Thr), and AQ4N within the calcium phosphate nanocarrier via a simple one-pot method. In the acidic TME, TACC NPs could be degraded to release Thr and Ce6, resulting in the destruction of tumor vessels and consumption of intratumoral oxygen under laser irradiation. Therefore, the intratumoral hypoxia level could be significantly aggravated, further leading to the enhanced chemotherapeutic effect of AQ4N. With the guidance of in vivo fluorescence imaging, the TACC NPs exhibited excellent tumor embolization/photodynamic/prodrug synergistic therapeutic effects with good biosafety.

摘要

由于缺氧肿瘤微环境(TME)不仅会限制治疗效果,还会导致肿瘤复发和转移,血管栓塞诱导的瘤内缺氧水平加剧是肿瘤治疗中的主要挑战之一。缺氧激活前药(HAPs)的化疗效果可通过强化缺氧来增强,肿瘤栓塞与基于HAP的化疗相结合展现出一种很有前景的癌症治疗策略。在此,通过一种简单的一锅法将光敏剂二氢卟吩e6(Ce6)、凝血酶(Thr)和AQ4N负载于磷酸钙纳米载体中,构建了一种具有多种途径有利于缺氧激活化疗的酸度响应纳米平台(TACC NP)。在酸性TME中,TACC NPs可降解以释放Thr和Ce6,从而在激光照射下导致肿瘤血管破坏和瘤内氧气消耗。因此,瘤内缺氧水平可显著加剧,进而导致AQ4N的化疗效果增强。在体内荧光成像的引导下,TACC NPs展现出优异的肿瘤栓塞/光动力/前药协同治疗效果以及良好的生物安全性。

相似文献

1
Acidity-responsive nanoplatforms aggravate tumor hypoxia via multiple pathways for amplified chemotherapy.酸度响应性纳米平台通过多种途径加重肿瘤缺氧以增强化疗效果。
Biomaterials. 2023 May;296:122094. doi: 10.1016/j.biomaterials.2023.122094. Epub 2023 Mar 15.
2
Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy.超分子胶束作为多功能治疗试剂用于协同光动力治疗和缺氧激活化疗。
Acta Biomater. 2021 Sep 1;131:483-492. doi: 10.1016/j.actbio.2021.07.014. Epub 2021 Jul 13.
3
Programmable therapeutic nanoscale covalent organic framework for photodynamic therapy and hypoxia-activated cascade chemotherapy.可编程治疗性纳米级共价有机框架用于光动力治疗和缺氧激活级联化疗。
Acta Biomater. 2022 Sep 1;149:297-306. doi: 10.1016/j.actbio.2022.07.003. Epub 2022 Jul 8.
4
Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy.基于产氧过氧化氢酶的前药纳米颗粒克服缺氧介导的化学-光动力疗法中的耐药性
Acta Biomater. 2020 Aug;112:234-249. doi: 10.1016/j.actbio.2020.05.035. Epub 2020 Jun 2.
5
An albumin-binding dimeric prodrug nanoparticle with long blood circulation and light-triggered drug release for chemo-photodynamic combination therapy against hypoxia-induced metastasis of lung cancer.一种具有长循环和光触发药物释放的白蛋白结合二聚体前药纳米颗粒,用于治疗低氧诱导的肺癌转移的化疗-光动力联合治疗。
Biomater Sci. 2021 May 18;9(10):3718-3736. doi: 10.1039/d1bm00284h.
6
ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy.ROS 敏感仿生纳米载体调节肿瘤乏氧用于协同光动力化疗。
Biomater Sci. 2019 Aug 20;7(9):3706-3716. doi: 10.1039/c9bm00634f.
7
Stimuli-Sensitive Linear-Dendritic Block Copolymer-Drug Prodrug as a Nanoplatform for Tumor Combination Therapy.刺激敏感线性-树枝状嵌段共聚物-前药作为肿瘤联合治疗的纳米平台
Adv Mater. 2022 Feb;34(8):e2108049. doi: 10.1002/adma.202108049. Epub 2022 Jan 13.
8
Near-infrared photoactivatable three-in-one nanoagents to aggravate hypoxia and enable amplified photo-chemotherapy.近红外光激活型三合一纳米制剂加重缺氧并增强光化疗。
Biomater Adv. 2024 Oct;163:213962. doi: 10.1016/j.bioadv.2024.213962. Epub 2024 Jul 19.
9
Targeted co-delivery of a photosensitizer and an antisense oligonucleotide based on an activatable hyaluronic acid nanosystem with endogenous oxygen generation for enhanced photodynamic therapy of hypoxic tumors.基于具有内源性氧生成的活化透明质酸纳米系统的光敏剂和反义寡核苷酸的靶向共递药用于增强缺氧肿瘤的光动力治疗。
Acta Biomater. 2022 Nov;153:419-430. doi: 10.1016/j.actbio.2022.09.025. Epub 2022 Sep 14.
10
Mitochondrial Ca-overloading by oxygen/glutathione depletion-boosted photodynamic therapy based on a CaCO nanoplatform for tumor synergistic therapy.基于碳酸钙纳米平台的氧/谷胱甘肽消耗增强型光动力疗法导致线粒体钙超载用于肿瘤协同治疗
Acta Biomater. 2022 Jan 1;137:252-261. doi: 10.1016/j.actbio.2021.10.016. Epub 2021 Oct 13.

引用本文的文献

1
Recent Advances in Strategies to Enhance Photodynamic and Photothermal Therapy Performance of Single-Component Organic Phototherapeutic Agents.增强单组分有机光治疗剂光动力和光热治疗性能策略的最新进展
Adv Sci (Weinh). 2025 Feb;12(7):e2409157. doi: 10.1002/advs.202409157. Epub 2025 Jan 10.
2
High-temperature PTT/CDT coordination nanoplatform realizing exacerbated hypoxia for enhancing hypoxia-activated chemotherapy to overcome tumor drug resistance.高温 PTT/CDT 协同纳米平台实现加剧缺氧以增强缺氧激活化疗克服肿瘤耐药性。
J Nanobiotechnology. 2024 Jun 26;22(1):374. doi: 10.1186/s12951-024-02653-8.
3
GSH-Triggered/Photothermal-Enhanced HS Signaling Molecule Release for Gas Therapy.
用于气体治疗的谷胱甘肽触发/光热增强硫化氢信号分子释放
Pharmaceutics. 2023 Oct 10;15(10):2443. doi: 10.3390/pharmaceutics15102443.